Shoichiro Mizukami

Shoichiro Mizukami

Auto-generated profile, based on publicly available information

Shoichiro Mizukami

Division of Gastroenterological and Transplant Surgery, Department of Surgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2025 in Cancers
Verified
Journal Article
Open access
PDF file
HYHIDEKI YOKOO
HIDEKI YOKOO
SMShoichiro Mizukami
Shoichiro Mizukami
HTHiroyuki Takahashi
Hiroyuki Takahashi
TTTomoki Takizawa
Tomoki Takizawa
KEKatsuro Enomoto
Katsuro Enomoto
KIKoji Imai
Koji Imai
Background: Hepatocellular carcinoma (HCC) larger than 10 cm has a poor prognosis, with high recurrence rates, particularly distant metastases. This study examined whether lenvatinib treatment followed by liver resection improves the outcomes for large HCCs compared with upfront surgery. Methods: We retrospectively analyzed 30 patients with HCC larger than 10 cm who underwent hepatectomy at our institution between January 2008 and December 2023. The study cohort included 30 patients: 9 received preoperative lenvatinib treatment followed by hepatectomy (LEN group), while 21 patients underwent upfront surgery (UFS group). We compared the clinicopathological characteristics, surgical outcomes, recurrence patterns, and survival between the two groups. Results: The median duration of lenvatinib administration was 1.8 months, with partial response in two patients (22.2%) and stable disease in seven patients (77.7%). While lenvatinib treatment significantly decreased serum albumin levels (p < 0.05) and increased ALBI scores (p = 0.03), the surgical outcomes including blood loss, operation time, and complication rates were comparable between the two groups. The 3-year recurrence-free survival rate was significantly higher in the LEN group compared with the UFS group (66.7% vs. 16.1%, p = 0.027). The 3-year overall survival rate was also higher in the LEN group, though not statistically significant (85.7% vs. 56.1%, p = 0.059). Notably, distant metastasis rates were lower in the LEN group compared with the UFS group (11.1% vs. 47.6%, p = 0.10). Conclusions: Preoperative lenvatinib treatment followed by hepatectomy for large HCC (> 10 cm) may reduce recurrence, particularly distant metastases, and potentially improve long-term survival. This approach may be a promising strategy for large HCCs, which traditionally have a poor prognosis with upfront surgery alone.

4 March 2025 in Surgical Innovation
Verified
Journal Article
Closed access
SMShoichiro Mizukami
Shoichiro Mizukami
TSTatsuya Shonaka
Tatsuya Shonaka
TTTomohiro Takeda
Tomohiro Takeda
HTHiroki Takahata
Hiroki Takahata
RSRyotaro Shimazaki
Ryotaro Shimazaki
HYHideki Yokoo
Hideki Yokoo
Objective. This prospective comparative study evaluated the efficacy and relationship between laparoscopic origami crane training (LOCT) and the Fundamentals of Laparoscopic Surgery (FLS) score using 3D vs 2D laparoscopy. Methods. From 2020 to 2023, fourth-year medical students at Asahikawa Medical University created 20 origami cranes (1 per day) in a laparoscopic dry box. FLS scores were assessed 5 times, corresponding to every fifth crane. Primary outcomes included LOCT production time, quality, and FLS scores, analyzed using the Mann–Whitney U test and repeated-measures ANOVA. Results. Eighteen participants were divided into 2 groups: 8 in the 3D laparoscopy (3D) group and ten in the 2D laparoscopy (2D) group. At the end of the study, the 3D group (16.5 min) produced cranes significantly faster than the 2D group (27 min, P = 0.02). Repeated-measures ANOVA showed that the production time, origami crane score, and FLS score improved over time. The 3D group had a significantly shorter production time (F (1, 16) = 8, P = 0.01). The origami crane score was not significantly different between the groups (F (1, 7) = 3, P = 0.13) but tended to be higher in the 3D group. No significant differences were found in the FLS scores between the groups for any task. A significant negative correlation between LOCT production time and FLS score in both groups confirmed that shorter production time correlated with higher FLS scores. Conclusions. LOCT is effective for extraclinical laparoscopic training and correlates with FLS scores. 3D laparoscopy may help beginners develop depth perception, improve bimanual and hand-eye coordination, and enhance LOCT effectiveness.

1 August 2025 in Pancreas
Verified
Journal Article
Closed access
SMShoichiro Mizukami
Shoichiro Mizukami
KIKoji Imai
Koji Imai
HTHiroyuki Takahashi
Hiroyuki Takahashi
SSShingo MD Shimada
Shingo MD Shimada
NTNobue Bs Tamamura
Nobue Bs Tamamura
HYHideki Yokoo
Hideki Yokoo
Objectives: Pancreatic simple mucinous cysts (SMCs) are characterized by cystic lesions >1 cm in size, lacking ovarian-type stroma and lined by a single layer of bland epithelium. Although SMCs are typically considered benign, sporadic cases with KRAS mutations suggest its potential inclusion within the spectrum of low-grade mucinous neoplasms. This study reported a case of pancreatic SMC with co-occurring KRAS and GNAS mutations to discuss their potential implications in the management of pancreatic cystic lesions. Materials and Methods: A 54-year-old woman with a 5-year history of pancreatic cysts was initially diagnosed with a branch-duct intraductal papillary mucinous neoplasm presented with abdominal distension. Imaging revealed a rapidly enlarging cystic lesion, prompting spleen-preserving distal pancreatectomy. Targeted amplicon sequencing was performed on the resected cystic wall and background pancreatic tissues. In addition, a literature review of 127 reported SMC cases was conducted to analyze demographics, imaging findings, pathologic findings, and genetic mutations. Results: Histopathologic analysis confirmed SMC, and genetic testing revealed KRAS and GNAS mutations in the cyst walls. At 32 months after surgery, the patient remained recurrence-free. The median age of the 127 patients was 66 years. The common imaging features included cyst enlargement and wall enhancement. KRAS mutations were found in 35% of the 65 cases, and our case is the first to report GNAS mutations. Conclusion: This is the first report of pancreatic SMC with co-occurring KRAS and GNAS mutations. SMC should be considered a differential diagnosis of pancreatic cystic lesions. Surgical intervention may be warranted based on findings.

20 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
HTHiroki Takahata
Hiroki Takahata
HTHiroyuki Takahashi
Hiroyuki Takahashi
SMShoichiro Mizukami
Shoichiro Mizukami
KMKai Makino
Kai Makino
KIKoji Imai
Koji Imai
HYHIDEKI YOKOO
HIDEKI YOKOO
Unresectable multifocal hepatocellular carcinoma (HCC) is generally managed with systemic therapy, including immune checkpoint inhibitors and molecular targeted agents. When adequate tumor control is achieved, conversion to surgical resection may become feasible. A 59-year-old man with untreated chronic hepatitis C was found to have seven HCC lesions during magnetic resonance imaging surveillance. Systemic therapy with atezolizumab (1200 mg/body) plus bevacizumab (15 mg/kg) was initiated for unresectable multifocal HCC. After three cycles, contrast-enhanced computed tomography showed tumor shrinkage, with a 28% reduction in the sum of target lesion diameters, corresponding to stable disease according to Response Evaluation Criteria in Solid Tumors v1.1. The future liver remnant volume was 39.2%. After two additional cycles of atezolizumab monotherapy as bridging therapy, the patient underwent extended right hepatectomy, including resection of segment 4 and partial resection of segment 2. Pathological examination confirmed R0 resection, with viable tumor cells and focal necrosis. The postoperative course was uneventful, and antiviral therapy for hepatitis C resulted in a sustained virological response. The patient remains recurrence-free. Systemic therapy with atezolizumab plus bevacizumab enabled successful conversion surgery for seven HCC lesions. This multimodal approach may represent a viable treatment option for carefully selected patients with initially unresectable multifocal HCC.

16 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
HTHiroyuki Takahashi
Hiroyuki Takahashi
SMShoichiro Mizukami
Shoichiro Mizukami
TTTomoki Takizawa
Tomoki Takizawa
KMKai Makino
Kai Makino
YAYuki Adachi
Yuki Adachi
HYHIDEKI YOKOO
HIDEKI YOKOO
Background/Objectives: A postoperative recovery capacity-enhancement program, Enhanced Recovery After Surgery (ERAS), has recently been developed according to evidence regarding perioperative management, recognizing the importance of perioperative rehabilitation. We examined the effectiveness of perioperative rehabilitation in patients with sarcopenia undergoing hepato-biliary-pancreatic (HBP) surgery. Methods: We evaluated 155 patients who underwent high-level HBP surgery from August 2017 to December 2019. We recorded their preoperative nutritional index (prognostic nutritional index and controlling nutritional status (CONUT) score), skeletal muscle index (SMI), surgical operation, and postoperative course. SMI was measured by bioimpedance analysis using an InBody S10®. Results: We analyzed data for 155 patients, including 68 in the sarcopenia (S) group and 87 in the non-sarcopenia (NS) group, according to the Asian Working Group for Sarcopenia criteria. The CONUT score was significantly higher and the nutritional status was poorer in the S group than in the NS group. The number of diabetic cases was also significantly higher in the S group than in the NS group. There was no significant difference in serious postoperative complications (Clavien–Dindo grade ≥ IIIa) between the groups, including pleural effusion and ascites that was difficult to treat. There was also no significant difference in length of hospital stay between the two groups. Conclusions: Among patients undergoing HBP surgery, patients with sarcopenia are likely to have poorer nutritional status and SMI; however, perioperative rehabilitation may help to avoid serious postoperative complications and long-term hospitalization after surgery.

24 September 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
YAYuki Adachi
Yuki Adachi
SSShingo Shimada
Shingo Shimada
SMShoichiro Mizukami
Shoichiro Mizukami
TTTomoki Takizawa
Tomoki Takizawa
KEKatsuro Enomoto
Katsuro Enomoto
HYHIDEKI YOKOO
HIDEKI YOKOO
Background/Objectives: The impact of preoperative zinc (Zn) status on the survival and recurrence of patients with hepatocellular carcinoma (HCC) after hepatectomy remains unclear. This study aimed to clarify whether preoperative Zn deficiency affects the prognosis of patients with HCC undergoing initial curative hepatectomy. Methods: We retrospectively reviewed 105 patients who underwent initial curative hepatectomy for HCC at our institution (2011–2018). Preoperative Zn deficiency was defined as serum Zn < 70 µg/dL. Clinical and tumor parameters were compared between patients with and without Zn deficiency. Disease-free and overall survival were evaluated using the Kaplan–Meier method, and prognostic factors were identified via univariate and multivariate Cox proportional hazards analyses. Subgroup analyses were conducted based on age, gender, and etiology. Results: Among 105 patients, 46 (43.8%) showed Zn deficiency (Zn deficiency group), whereas 59 (56.2%) showed normal Zn (normal Zn group). Compared with the normal-Zn group, the Zn deficiency group showed significantly lower hemoglobin, prothrombin activity, serum albumin, and smaller tumor size (all p < 0.05). The Zn deficiency group experienced significantly worse disease-free survival (p = 0.015) but no difference in overall survival (p = 0.63). On multivariate analysis, zinc deficiency (hazard ratio [HR] 1.83, p = 0.040) and prothrombin activity (HR 0.98, p = 0.042) were independent predictors of worse disease-free survival. Subgroup analysis revealed that Zn deficiency was significantly associated with elevated recurrence risk in patients with HCV-related liver disease (HR 3.67, p = 0.013). Conclusions: Preoperative Zn deficiency is an independent predictor of worse DFS after curative hepatectomy. Although further large-scale studies are required to confirm these findings, evaluating preoperative Zn status may help identify patients at high risk of HCC recurrence.